KR101412157B1 - 항종양 활성을 갖는 캄프토테신 유도체 - Google Patents

항종양 활성을 갖는 캄프토테신 유도체 Download PDF

Info

Publication number
KR101412157B1
KR101412157B1 KR1020097001595A KR20097001595A KR101412157B1 KR 101412157 B1 KR101412157 B1 KR 101412157B1 KR 1020097001595 A KR1020097001595 A KR 1020097001595A KR 20097001595 A KR20097001595 A KR 20097001595A KR 101412157 B1 KR101412157 B1 KR 101412157B1
Authority
KR
South Korea
Prior art keywords
mmol
nmr
mhz
cdcl
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097001595A
Other languages
English (en)
Korean (ko)
Other versions
KR20090033456A (ko
Inventor
가브리엘레 폰타나
에지오 봄바르델리
카를라 만조티
아르투로 바타글리아
크리스티안 사모리
Original Assignee
인데나 에스.피.아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인데나 에스.피.아 filed Critical 인데나 에스.피.아
Publication of KR20090033456A publication Critical patent/KR20090033456A/ko
Application granted granted Critical
Publication of KR101412157B1 publication Critical patent/KR101412157B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
KR1020097001595A 2006-07-26 2007-07-13 항종양 활성을 갖는 캄프토테신 유도체 Expired - Fee Related KR101412157B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2006A001473 2006-07-26
IT001473A ITMI20061473A1 (it) 2006-07-26 2006-07-26 Derivati della camptotecina ad attivita antitumorale
PCT/EP2007/006243 WO2008011994A1 (en) 2006-07-26 2007-07-13 Camptothecin derivatives with antitumor activity

Publications (2)

Publication Number Publication Date
KR20090033456A KR20090033456A (ko) 2009-04-03
KR101412157B1 true KR101412157B1 (ko) 2014-06-25

Family

ID=38668829

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097001595A Expired - Fee Related KR101412157B1 (ko) 2006-07-26 2007-07-13 항종양 활성을 갖는 캄프토테신 유도체

Country Status (20)

Country Link
US (1) US8217053B2 (https=)
EP (1) EP2044079B1 (https=)
JP (1) JP5313894B2 (https=)
KR (1) KR101412157B1 (https=)
CN (1) CN101495486B (https=)
AU (1) AU2007278500B2 (https=)
BR (1) BRPI0714553B8 (https=)
CA (1) CA2658900C (https=)
DK (1) DK2044079T3 (https=)
ES (1) ES2561356T3 (https=)
HU (1) HUE027890T2 (https=)
IL (1) IL196653A (https=)
IT (1) ITMI20061473A1 (https=)
MX (1) MX2009000827A (https=)
NO (1) NO341812B1 (https=)
PL (1) PL2044079T3 (https=)
PT (1) PT2044079E (https=)
RU (1) RU2450008C2 (https=)
SI (1) SI2044079T1 (https=)
WO (1) WO2008011994A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2907824T3 (en) * 2012-10-11 2018-07-23 Daiichi Sankyo Co Ltd ANTIBODY-drug conjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
KR101586030B1 (ko) * 2014-01-22 2016-01-15 주식회사 엘지생활건강 캄프토테신을 유효성분으로 포함하는 체모 성장 억제용 조성물
SI3466976T1 (sl) 2014-01-31 2021-12-31 Daiichi Sankyo Company, Limited Anti-her2 konjugat protitelesa-zdravila
EP4180455A1 (en) 2015-06-29 2023-05-17 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
BR112019011794A2 (pt) 2016-12-12 2019-10-29 Daiichi Sankyo Co Ltd composição farmacêutica, e, método terapêutico.
CA3050668C (en) 2017-01-17 2023-08-15 Daiichi Sankyo Company, Limited Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
TW202532102A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
BR112020003466B1 (pt) 2017-08-31 2023-12-12 Daiichi Sankyo Company, Limited Métodos de produção de composto, e, composto
ES3057444T3 (en) 2017-08-31 2026-03-02 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
TW202537643A (zh) 2018-07-31 2025-10-01 日商第一三共股份有限公司 抗體-藥物結合物之用途
US10568873B1 (en) * 2019-02-14 2020-02-25 United Arab Emirates University Safranal-sorafenib combination therapy for liver cancer
CN112225745B (zh) * 2020-11-16 2021-10-12 烟台大学 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
JP2024523422A (ja) * 2021-06-17 2024-06-28 ミンフイ ファーマシューティカル （ハンチョウ） リミテッド 抗腫瘍化合物およびその応用
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
CN121194979A (zh) * 2023-05-08 2025-12-23 甘李药业股份有限公司 喜树碱衍生物、接头、配体-药物偶联物及其医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
FR2757515B1 (fr) * 1996-12-20 2000-05-05 Sod Conseils Rech Applic Formes prodrogues et nouveaux analogues de la camptothecine, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
US6881555B2 (en) * 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
KR20040039404A (ko) * 2001-09-25 2004-05-10 닥터 레디스 레보러터리즈 리미티드 20(에스)-캄포테신의 약제학적으로 수용가능한 염
US20060084167A1 (en) * 2004-10-16 2006-04-20 Cohenford Menashi A Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin

Also Published As

Publication number Publication date
BRPI0714553B8 (pt) 2021-05-25
US8217053B2 (en) 2012-07-10
JP5313894B2 (ja) 2013-10-09
CN101495486A (zh) 2009-07-29
WO2008011994A1 (en) 2008-01-31
US20100120816A1 (en) 2010-05-13
SI2044079T1 (sl) 2016-02-29
DK2044079T3 (en) 2016-02-29
BRPI0714553A2 (pt) 2013-03-26
IL196653A0 (en) 2009-11-18
KR20090033456A (ko) 2009-04-03
MX2009000827A (es) 2009-02-03
NO20090251L (no) 2009-01-16
NO341812B1 (no) 2018-01-29
EP2044079A1 (en) 2009-04-08
IL196653A (en) 2015-04-30
CN101495486B (zh) 2013-05-15
PL2044079T3 (pl) 2016-06-30
BRPI0714553B1 (pt) 2020-11-17
RU2450008C2 (ru) 2012-05-10
PT2044079E (pt) 2016-03-09
AU2007278500A1 (en) 2008-01-31
ITMI20061473A1 (it) 2008-01-27
CA2658900A1 (en) 2008-01-31
JP2009544634A (ja) 2009-12-17
HUE027890T2 (en) 2016-11-28
RU2009102243A (ru) 2010-07-27
AU2007278500B2 (en) 2012-06-07
ES2561356T3 (es) 2016-02-25
AU2007278500A2 (en) 2010-09-09
HK1135691A1 (en) 2010-06-11
EP2044079B1 (en) 2015-12-09
CA2658900C (en) 2015-09-15

Similar Documents

Publication Publication Date Title
KR101412157B1 (ko) 항종양 활성을 갖는 캄프토테신 유도체
KR101496374B1 (ko) 항종양 활성을 갖는 캄프토테신 유도체
JP5198447B2 (ja) 抗腫瘍活性を有するカンプトテシン誘導体
HK1135693B (en) Camptothecin derivatives with antitumor activity
HK1135692B (en) Camptothecin derivatives with antitumor activity

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170605

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180525

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190529

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210620

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210620